BNC-210

Neuphoria Therapeutics has received a US$15M milestone payment from Merck following the initiation of a Phase 2 trial for MK-1167 in Alzheimer's disease, extending the company's cash runway to Q3 2026.

Neuphoria Therapeutics Inc. has successfully regained compliance with Nasdaq's Minimum Bid Price Requirement, ensuring its continued listing on the exchange. The company, which recently re-domiciled from Australia to Delaware, is advancing its clinical trials, including phase 3 trials for BNC210, a treatment for social anxiety disorder and post-traumatic stress disorder. This development marks a significant milestone for Neuphoria Therapeutics, highlighting its commitment to overcoming financial and regulatory challenges while focusing on innovative medical treatments.

Bionomics' BNC210 demonstrated statistically significant improvement in PTSD symptom severity compared to placebo at Week 12, with benefits observed as early as Week 4.

Bionomics initiates Phase 3 trial for BNC210 in social anxiety disorder (SAD) after successful regulatory interactions and IP portfolio expansion, with data readout anticipated in Q3 2025.